Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024 Apr 16, 2024
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024 Feb 13, 2024
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap Jan 18, 2024
Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025 Jan 4, 2024
